According to the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus cisplatin and capecitabine/5-fluorouracil (5-FU) is standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer. We examined the relative efficacy and safety of alternative trastuzumab-based cytotoxic backbone regimens compared to the standard ToGA regimen using meta-analysis. We searched Medline, EMBASE, CENTRAL and ASCO and ESMO up to March 2017 for studies investigating alternative first-line trastuzumab-based regimens for HER2-positive oesophagogastric cancer, defined as high protein expression IHC31 or IHC21 and gene amplification by in situ hybridisation. We compared primary outcome overall survival (OS) of alternative trastuzumab-based regimens to the ToGA regimen. Hazard ratios (HRs) and 95% confidence intervals (95%CI) were calculated by extraction of the published Kaplan-Meier curves. Incidence counts and toxicity sample-sizes were extracted for adverse events and compared using single-arm proportion meta-analysis in R. Fifteen studies (N 5 557 patients) were included. OS was significantly longer with regimen trastuzumab plus doublet oxaliplatin and capecitabine/5-FU (median OS 5 20.7 months) versus ToGA (16.0 months, HR 5 0.75, 95% CI 5 0.59-0.99) and was less toxic. Trastuzumab plus doublet cisplatin and S-1 showed no OS difference versus ToGA, but showed a different toxicity profile, including less hand-foot syndrome. Trastuzumab plus cisplatin or capecitabine as singlet backbone showed significantly worse survival and more toxicity versus ToGA regimen. Trastuzumab with triplet cytotoxic backbones or with bevacizumab and doublet cytotoxic backbone showed no survival benefit and more toxicity. In conclusion, trastuzumab plus doublet cytotoxic backbone containing oxaliplatin is preferable over the ToGA regimen with cisplatin. S-1 can substitute capecitabine or 5-FU when specific toxicities are encountered.
Introduction
Since the publication of the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus the doublet cytotoxic backbone containing cisplatin and capecitabine or 5-fluorouracil (5-FU) is the standard first line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer. 1, 2 The ToGA trial included patients with HER2 protein overexpression indicated by a immuhistochemistry (IHC) score of 31 alone or with gene amplification by fluorescent in situ hybridisation (FISH), irrespective of IHC score. The median overall survival (OS) was significantly longer in the patient group receiving trastuzumab plus cisplatin and capecitabine/5-FU compared to those who received cisplatin and capecitabine/5-FU without trastuzumab, 13.8 months versus 11.0 months, respectively. Moreover, a pre-planned sub-analysis indicated the survival benefit of adding trastuzumab to chemotherapy more pronounced in patients with high HER2 expression, IHC31, or with IHC21 and FISH1, with a median OS of 16.0 months compared to 11.8 months for those allocated to chemotherapy alone. Therefore, in most countries, trastuzumab plus chemotherapy is indicated for HER2-positive patients with high protein expression IHC31 or with IHC21 and gene amplification by FISH1.
Previous research has shown that cisplatin-containing doublet regimens were associated with lower efficacy and with more toxicity compared to non-cisplatin containing doublets. [5] [6] [7] Therefore, the substitution of cisplatin for oxaliplatin has become increasingly popular, as oxaliplatin is associated with less toxicity, and may even be more effective. [8] [9] [10] [11] In addition, there is evidence that the oral fluoropyrimidine S-1, which is the standard first-line fluoropyrimidine in Asia, is associated with less toxicity compared to capecitabine in Asian patients and compared to conventional 5-FU in both Asian and Western patients. [12] [13] [14] [15] Therefore, it may be questioned whether cisplatin and capecitabine or 5-FU is the optimal cytotoxic backbone for trastuzumab treatment in patients with HER2 positive advanced oesophagogastric cancer.
In the past few years, several studies have been conducted to investigate the potential of alternative backbone cytotoxic agents for trastuzumab. However, these were small single arm studies and direct comparisons to the standard ToGA regimen are lacking. Therefore, we conducted a meta-analysis to examine the relative efficacy and safety of alternative trastuzumab-based backbone regimens compared to the standard ToGA regimen.
Material and Methods

Literature search
We searched databases Medline, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) and meeting abstracts from the American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) up to March 2017. We used a broad search to retrieve all relevant references by combining the medical subject headings (MeSH-terms) and texts words for neoplasms of both the oesophagus and stomach with those for HER2 receptor expression or gene amplification. For a more detailed description of the search terms, see Supporting Information Table S1 . Two authors (A.C. and L.d.W.) independently screened the titles, abstracts and full-texts and disagreements were discussed with a third arbiter (E.t.V.) until consensus was reached.
Study selection
The inclusion criteria were: (i) patients with pathologically proven HER2-positive metastatic, unresectable or recurrent adenocarcinoma of the stomach, oesophagus or gastroesophageal junction; (ii) HER2-positivity was defined as high protein expression IHC31 or with IHC21 and gene amplification by any in situ hybridisation method (ISH); (iii) First-line trastuzumab-based systemic therapy with cytotoxic backbones other than the conventional ToGA backbone cisplatin and capecitabine or 5-FU; (iv) Prospective or retrospective cohort studies The exclusion criteria were: (i) HER2-positivivity defined other than IHC31 or IHC21 with ISH1; (ii) any beyond first-line therapy; (iii) HER2-targeted agent other than trastuzumab; (iv) Cisplatin and capecitabine or 5-FU as cytotoxic doublet backbone; (v) patient-control studies or case-reports.
Quality assessment
A modified version of the Newcastle Ottawa Scale for cohort studies was used to assess the quality (Supporting Information Table S2 ). Studies were scored as low (0-4 points), moderate (5-8 points) or high quality (9-11 points).
Data extraction and statistical analysis
Our primary outcome was OS. We compared OS of alternative trastuzumab-based regimens to trastuzumab plus cisplatin and capecitabine/5-FU of the IHC31 or IHC21/ISH1 subgroup in the ToGA trial. To this aim, we extracted the median OS and 95% confidence intervals (95% CI), the number of events, the censor tick-marks at specific time points on the curve, the number at risk at specific time intervals, and we digitalized the Kaplan-meier curves using Windows Plot Digitizer (version 2.6.3). From the extracted values, we estimated the number of events and censors on each time interval. 16 These data were used to recalculate the Kaplan-Meier curves for each regimen until the shape of our curves, number of events, censors and numbers at risk were in complete concordance with those provided in the original study reports. 16, 17 Kaplan-Meier curves were plotted using Graphpad Prism (version 5). Data from studies with equal regimens were pooled. Next, hazard ratios (HRs) and 95% CI were calculated for the OS comparison of all alternative trastuzumabbased regimens to the ToGA regimen. As heterogeneity between single-arm studies using time-to-event data could not formally be calculated, the median OS was also used to indicate whether the treatment effect was similar in each individual study investigating the same regimen.
What's new?
Standard treatment for oesophagogastric cancers that are positive for human epidermal growth factor receptor 2 (HER2) consists of trastuzumab plus cisplatin and capecitabine or 5-fluorouracil (5-FU). Cisplatin-containing doublet regimens, however, are known be more toxic and less effective than regimens without cisplatin. In this meta-analysis, alternative trastuzumabbased therapies were compared to the standard cisplatin-containing regimen in the treatment of HER2-positive metastatic oesophagogastric adenocarcinomas. The substitution of cisplatin with oxaliplatin was associated with increased survival and reduced toxicity. Hand-foot syndrome was reduced, without a compromise in efficacy, by replacing capecitabine with 5-FU or the oral fluoropyrimidine S-1.
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In addition, incidence counts and toxicity sample sizes were extracted for grade 1-2 (mild) and grade 3-4 (severe) adverse events (AE). Pooled proportions and 95%CI were calculated with the Freeman-Tukey double arcsine transformation from AE incidence counts and toxicity populations. Single-arm proportion meta-analysis was conducted using the Metafor package in R. We compared pooled proportions of all regimens to those of the ToGA regimen with z-tests for proportions.
The report of the ToGA trial neither provided a KaplanMeier curve for progression-free-survival (PFS) nor for objective response rate (ORR) for the IHC31 or IHC21/ISH1 subgroup and therefore a direct comparison of PFS and ORR of alternative trastuzumab regimens to those of the ToGA regimen was not possible. As only the median PFS was available for the ToGA IHC31 or IHC21/ISH1 subgroup, and the ORR of the full analysis ToGA population, we showed these alongside with the median PFS and ORR of the alternative trastuzumab regimens for exploratory reasons.
All statistical tests in this systematic review were performed using a 5% level of statistical significance. This systematic review was conducted according to PRISMAguidelines (Supporting Information Table S3 ).
Results
Description of the included studies
A total of 5,670 unique titles were retrieved through the database search, of which 26 studies remained after screening the titles and abstracts. After full-text assessment, 15 were excluded and 11 were found eligible. In addition, four studies retrieved from the conference search were eligible (Supporting Information Fig. S1 ). In total, 15 studies containing 557 patients were included, investigating nine alternative backbone regimens (Table 1) . [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] The ToGA trial included 228 patients in the trastuzumab plus cisplatin and capecitabine/5-FU arm. In the doublet and triplet backbone studies, no major differences in patient population were observed compared to the ToGA population (Table 1) . However, some studies investigating singlet backbones included older patients as compared to the ToGA trial. Of the published studies, 9 of 11 studies (82%) were of high quality and two (18%) were of moderate quality (Supporting Information Table S2 ). Of the other four studies that were reported as conference presentation only, two were rated as high quality and two as moderate quality.
Efficacy
Kaplan-Meier curves for OS could be extracted from 13 study reports (Table 2 ). For doublet backbone regimens, OS was significantly longer in trastuzumab plus oxaliplatin and capecitabine/5-FU containing regimens compared to ToGA regimen, with a median OS of, respectively, 20.7 months (3 studies, n 5 140) versus 16.0 months (n 5 228), pooled HR 5 0.75 (95%CI 5 0.59-0.99), p < 0.05 (Table 2 ; Fig. 1 ). The doublet backbone regimen trastuzumab plus cisplatin and S-1 showed no significant difference in OS compared to ToGA (Table 2 ; Fig. 1 ). In contrast, trastuzumab combined with a single backbone agent cisplatin or capecitabine showed significantly worse survival compared to the ToGA regimen ( Table 2 ). In addition, the combination of trastuzumab with S-1-alone showed no difference in OS compared to ToGA, although the HR tended to be more in favour of ToGA. The addition of a triplet cytotoxic backbone including docetaxel, platinum and fluoropyrimidine to trastuzumab did not result in prolonged OS in two studies (Table 2) . In one study, the vascular endothelial growth factor-A inhibitor bevacizumab was added to trastuzumab and both targeted therapies were combined with a cytotoxic triplet backbone consisting of docetaxel, oxaliplatin and capecitabine. However, no survival benefit was detected for this regimen compared to ToGA. The median OS from each individual study investigating the same regimen were comparable, indicating that the treatment effect should be similar among the studies As exploratory assessment, the median PFS and ORR for all backbone studies and for the IHC31 or IHC21 and ISH1 subgroup of the ToGA study are shown in Table 2 . In short, the median PFS and ORR of trastuzumab plus doublet oxaliplatin and capecitabine/5-FU and of trastuzumab combined with any cytotoxic triplet backbone tended to be higher compared to ToGA, whereas the median PFS tended to be lower for trastuzumab plus singlet backbones. The median PFS and ORR of the other regimens were in concordance with those of the ToGA regimen.
Toxicity
Trastuzumab plus oxaliplatin and capecitabine/5-FU was associated with less grade 1-2 anaemia, anorexia, less grade 1-2 and grade 3-4 vomiting and less grade 3-4 neutropenia and diarrhoea, compared to the ToGA regimen (Table 3) . However, more grade 1-2 anaemia, grade 1-2 thrombocytopenia, and grade 1-2 and grade 3-4 neuropathy was observed with trastuzumab plus oxaliplatin and capecitabine/5-FU. Compared to ToGA regimen, the doublet backbone regimen of trastuzumab plus cisplatin and S-1 was associated with less grade 1-2 diarrhoea, grade 1-2 hand-foot syndrome and grade 1-2 vomiting, but with more grade 1-2 abdominal pain, grade 1-2 fatigue, grade 1-2 mucositis, grade 3-4 anorexia and LVEF decrease 10%.
The singlet backbone regimens showed mixed toxicity profiles, including less grade 3-4 neutropenia for trastuzumab plus S-1 and for trastuzumab plus cisplatin, compared to the ToGA regimen. However, other grade 1-2 adverse events, such as anaemia, thrombocytopenia, mucositis, pigmentation and asthenia, occurred more frequent with the singlet backbone regimens.
Triplet backbone regimens including docetaxel, cisplatin and S-1 or docetaxel, oxaliplatin and capecitabine showed more haematological toxicity compared to the ToGA regimen. Also, trastuzumab with bevacizumab plus triplet (75) 13 (25) 48 (94) 3 (6) 18 (35) 33 (65) Ryu et al. (89) 6 (11) 51 (93) 4 (7) 55 (100) Soularue et al. Retrospective multicentre cohort 27 (79) 63 (30-82) 30 (88) 4 (12) 27 (79) 7 (21) 24 (71) (84) 4 (16) 23 (92) 2 (8) 17 (68) 8 (32) Baseline characteristics for the total number of patients in the trastuzumab-arm of the ToGA trial and for all alternative cytotoxic backbone studies were given. In all studies, trastuzumab was dosed as 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks. S-1 was dosed based on body surface area: BSA The tumour location of the rest of the patient was not specified as isolated GEJ or gastric. 3 Median time to progression was given instead of median progression free survival.
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backbone docetaxel, oxaliplatin and capecitabine was associated with more grade 1-2 diarrhoea and grade 3-4 leukopenia.
Discussion
We investigated the efficacy and safety of alternative trastuzumab backbones using meta-analysis compared to the conventional trastuzumab plus cisplatin and capecitabine/5-FU regimen used in the ToGA trial for patients with HER-2 positive advanced oesophagogastric cancer. This is the first meta-analysis in which the regimens were compared directly and the results may therefore have direct implications for treatment in clinical practice. Trastuzumab plus a doublet backbone consisting of oxaliplatin and capecitabine/5-FU was associated with significantly longer survival and with a more convenient toxicity profile compared to the ToGA regimen. Trastuzumab plus doublet backbone cisplatin and S-1 showed no difference in survival compared to ToGA, but had a different toxicity profile with less hand-foot syndrome.
Our results were in-line with previously published studies and meta-analyses on cytotoxic treatment in first-line regimens, which showed a more convenient toxicity profile of S-1 compared to capecitabine and 5-FU. [12] [13] [14] [15] Also in line with previous evidence is the increased efficacy and decreased toxicity of oxaliplatin compared to cisplatin. [5] [6] [7] [8] 10, 11 The increased efficacy might be directly related to the higher incidence of toxicity with cisplatin, such as neutropenia and gastrointestinal adverse events, especially in elder patients and in more frail patients. Also, some adverse events, for example diarrhoea or vomiting, might occur in the first cycles, while on the other hand, neuropathy as the main adverse event of oxaliplatin usually occurs after a longer treatment period. Therefore, patients might tolerate oxaliplatin-based regimens for a longer time period, and hereby increasing exposure to the therapeutic effect of oxaliplatin. [5] [6] [7] [8] 10, 11 In accordance with metastatic breast cancer, anti-HER2 targeted therapy may be combined with a wide variety of cytotoxic agents. 33, 34 Therefore, it is recommended to use an optimal cytotoxic backbone regimen in terms of survival and toxicity. Based on our data for advanced oesophagogastric cancer, preferably cisplatin should be substituted for oxaliplatin in the conventional doublet backbone regimen. Also, S-1 can be used instead of the fluoropyrimidines capecitabine or 5-FU based on differences in toxicity profile, without compromising survival.
Trastuzumab combined with singlet backbones were associated with decreased survival and somewhat increased toxicity compared to ToGA. However, the fact that older and frailer patients were included in two of these singlet backbone studies is a plausible explanation for these findings, and the results should therefore be interpreted with caution. 22, 32 The addition of triplet cytotoxic backbones to trastuzumab consisting of docetaxel, platinum and fluoropyrimidine did not increase survival over ToGA, as did regimens in which trastuzumab was combined with another targeted agent bevacizumab plus a cytotoxic triplet backbone. This implicates that there is currently no role for triplet cytotoxic backbones and for bevacizumab in the first-line trastuzumab-based regimen. Recognizing the need for further improvement of the first-line trastuzumab-based treatment, the results of the JACOB trial, investigating the efficacy of adding the HER3 inhibitor pertuzumab to trastuzumab, platinum and fluoropyrimidine, are eagerly awaited. 
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Some limitations of this meta-analysis should be acknowledged. First, as randomized controlled trials investigating different trastuzumab-based backbone regimens are lacking, this meta-analysis is based on cross-study comparisons between single-arm studies and the trastuzumab-arm of the ToGA trial. Therefore, HRs for OS could only be estimated. However, instead of using only the number of events and total sample sizes for estimating HR, which is a common method, in addition we digitalized the published Kaplan-Meier curve, the number of censored patients, the censor tick-marks at specific time points on the Kaplan-Meier curve and the number at risk at specific time intervals. Eventually, the KaplanMeier curves were recalculated, until the shape of the curve, the number of events, censors and numbers at risk were in concordance with those provided in the original study reports, thus providing robust data for the survival analysis. 16, 17 Also, in cross-study comparisons there may be differences in patient characteristics among the treatment groups that could not be accounted for. Finally, direct statistical comparisons in PFS and ORR outcomes between IHC31 or IHC21/ISH1 patients receiving alternative trastuzumab regimens to those receiving the ToGA regimen were not possible and we were restricted to exploratory analyses only. However, OS was the primary outcome of the ToGA trial and may therefore be regarded leading for decision making. The exploratory results of PFS and ORR showed a similar pattern as OS.
In conclusion, this meta-analysis showed that trastuzumab plus a doublet cytotoxic backbone consisting of oxaliplatin and fluoropyrimidine is preferable compared to cisplatin in the conventional ToGA regimen for patients with HER2 positive advanced oesophagogastric cancer. Also, capecitabine or 5-FU can be substituted for S-1 depending on the preferred toxicity profile for the individual patient.
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